Remarks

Reconsideration of this Application is respectfully requested. Claims 3 and 47-50 are pending in the application, with claims 3 and 47-50 being the independent claims. Claims 3 and 47-50 are pending and under consideration. Under 37 C.F.R. § 1.116(b), claims 47-50 have been amended to place them in better form for allowance or appeal. Support for these amendments may be found, *inter alia*, in the specification as-filed at paragraphs [0003], [0005], [0009], [0017], [0022-0025], [0028], [0032], [0033], [0036], [0037], [0042], [0049], [0060-0064], [0068], [0069], Examples 1-7 [0073-0087], Examples 8-11 [0090-0102] and Table 1. These changes are believed to introduce no new matter, and their entry is respectfully requested. Claims 51-70 have been withdrawn by the Examiner as allegedly being directed to a non-elected invention.

Based on the following remarks, Applicants respectfully request that the Examiner reconsider all outstanding objections and rejections and that they be withdrawn.

Election/Restriction

The Examiner has withdrawn newly-presented claims 51-70 as allegedly being directed to a distinct invention from the compositions recited in claims 3 and 47-50. (Office Action of 10/26/2006, hereinafter "OA", at page 2.) The Examiner asserts that "[s]ince applicant has received an action on the merits for the originally presented invention, this invention has been constructively elected by original presentation of prosecution on the merits," citing MPEP § 821.03. (*See Id.*) Applicants respectfully traverse the withdrawal of claims 51-70.

A.   Claims 54, 58, 62, 66 and 70

Applicants respectfully assert that claims 54, 58, 62, 66 and 70 should be rejoined with the claims under consideration in the present application because they depend from either allowable claim 3 or claims 47-50, which are also believed by Applicants to be in condition for allowance. (*See* pages 12-19, *infra*). Presently-withdrawn claims 54, 58, 62, 66 and 70 are directed to a method for producing a polypeptide using the nucleic acid sequences recited in claims 3 and 47-50 (*i.e.*, the nucleic acid sequence of SEQ ID NO: 115 and sequences having 95%, 90%, 85% or 83% identity with SEQ ID NO:115). The USPTO published a Notice in the March 26, 1996 Official Gazette setting forth the guidelines for the treatment of product and process claims in light of the Federal Circuit's decisions in *In re Ochiai*, 71 F.3d 1565 (Fed. Cir. 1995), and *In re Brouwer*, 77 F.3d 422 (Fed. Cir. 1996). *See* 1184 OG 86 (March 26, 1996). Specifically, the Notice states that in the case of an elected product claim, rejoinder will be permitted when a product claim is found allowable and the withdrawn process claim depends from or otherwise includes all the limitations of an allowed product claim. *See Id.*

In the present case, the Examiner has essentially restricted between the product recited in claims 3 and 47-50, and methods of using the product, as recited in claims 54, 58, 62, 66 and 70. In the Office Action dated October 24, 2006, the Examiner stated that claim 3 is allowable because "the prior art does not describe an isolated nucleic acid comprising SEQ ID NO:115." (OA at page 4). Although the Examiner has rejected claims 47-50 under 35 U.S.C. §112, first paragraph, Applicants believe this rejection will be overcome, and that presently-pending claims 47-50 are in condition for allowance. (*See* pages 12-19, *infra*). Thus, in view of the guidelines set forth in the March 26, 1996

Official Gazette Notice, as well as the Federal Circuit's decisions in *In re Ochiai* and *In re Brouwer*, Applicants respectfully request reconsideration and rejoinder of withdrawn method claims 54, 58, 62, 66 and 70 with presently-pending product claims 3 and 47-50.

B.   Claims 51-53, 55-57, 59-61, 63-65 and 67-69

The Examiner has also withdrawn claims 51-53, 55-57, 59-61, 63-65 and 67-69 from consideration, asserting that they are directed to distinct compositions "such as a genetically engineered host cell, comprising a recombinant vector comprising a distinct polynucleotide sequence." (OA at page 2.) Applicants respectfully traverse this restriction.

(i)   Claims 51-53

Claims 51-53 should be rejoined and fully examined for patentability in accordance with 37 CFR §1.104 because they were presented for examination prior to final rejection or allowance, and require all the limitations of allowable claim 3. *See* MPEP §821.04(a). Claims 51-53 depend directly or indirectly from claim 3, and are directed to compositions requiring the allowable product of claim 3 (SEQ ID NO: 115). In the Office Action of October 24, 2006, the Examiner essentially restricted claims 51-53 from the present application by withdrawing them as allegedly being directed to a non-elected invention. (OA at page 2). Applicants respectfully traverse this restriction.

Section 821.04(a) of the MPEP states that an amendment presenting additional claims that depend from, or otherwise require all the limitations of, an allowable claim *will be entered as a matter of right* if the amendment is presented prior to final rejection or allowance, whichever is earlier. *See* MPEP 821.04(a). In this case, the additional claims presented in the September 13, 2006 Amendment and Reply (including claims 51-

53) were submitted before a final rejection was issued. Additionally, the Examiner has

indicated that claim 3, directed to the nucleic acid sequence of SEQ ID NO:115, is

allowable. (*See* OA, page 4). Claims 51-53 depend directly or indirectly from claim 3,

and recite compositions requiring the allowable product of claim 3 (SEQ ID NO: 115).

Furthermore, claim 3 is a generic linking claim with regard to claims 51-53. *See* MPEP

§809. When all claims directed to the elected invention are allowable, should any

linking claim be allowable, the restriction requirement between the linked inventions

must be withdrawn. *See* MPEP §809. Any claims directed to the nonelected

invention(s), previously withdrawn from consideration, and which depend from or

require all the limitations of the allowable linking claim must be rejoined and will be

fully examined for patentability. *See* MPEP §809. Thus, according to MPEP §§ 809 and

821.04(a), at least claims 51-53, all of which depend directly or indirectly from

allowable claim 3 should have been considered in the Office Action of October 24, 2006.

Accordingly, Applicants respectfully assert that claims 51-53 should be rejoined with the

presently-pending claims and fully examined for patentability in accordance with 37

CFR §1.104.

(ii)   Claims 55-57, 59-61, 63-65 and 67-69

Claims 55-57, 59-61, 63-65 and 67-69 should be rejoined and fully examined for

patentability in accordance with 37 CFR §1.104 because they depend directly or

indirectly from claims 47-50, and although the Examiner has rejected independent claims

47-50 under 35 U.S.C. §112, first paragraph, this rejection is believed to have been

overcome, putting claims 47-50 in condition for allowance. *See* MPEP §821.04(a).

Claims 55-57, 59-61, 63-65 and 67-69 are directed to compositions such as recombinant

vectors and genetically engineered host cells, requiring either the allowable product of

claim 3 (SEQ ID NO: 115), or sequences that have 95%, 90%, 85% or 83% identity with

SEQ ID NO: 115. In the Office Action of October 24, 2006, the Examiner essentially

restricted claims 55-57, 59-61, 63-65 and 67-69 from the present application by

withdrawing them as being allegedly directed to a non-elected invention. (OA at page 2).

Applicants respectfully traverse this restriction.

Section 821.04(a) of the MPEP states that when restriction has been required

between independent or distinct products, or between independent or distinct processes,

and all claims directed to an elected invention are allowable, any restriction requirement

between the elected invention and any nonelected invention that depends from or

otherwise requires all the limitations of an allowable claim should be withdrawn. *See*

MPEP §821.04(a). In this case, although genetically engineered host cells and

recombinant vector could technically be classified into a different class and subclass, the

search for SEQ ID NO:115 or sequences having 95%, 90%, 85% or 83% identity with

SEQ ID NO: 115 would be coextensive with the different classes comprising host cells

and recombinant vectors. As noted above, the Examiner stated in the Office Action of

October 24, 2006, that SEQ ID NO: 115 is found to be free of the prior art. (OA, page 4).

Thus, any composition that includes SEQ ID NO: 115 and is not a product of nature will

also be free of the prior art. Furthermore, Applicants assert that examination of claims

55-57, 59-61, 63-65 and 67-69 would not impose a burden on the examiner because the

examiner has not established that the search for SEQ ID NO:115 would not have

provided results pertinent to these claims. *See* MPEP §808.02. Accordingly, since

claims 55-57, 59-61, 63-65 and 67-69 are directed to compositions encompassing an

allowable product, Applicants respectfully request that they be rejoined and fully

examined for patentability in accordance with 37 CFR §1.104.

Rejections under 35 U.S.C. § 112, first paragraph

A.   Claims 47-50 do not contain new matter

The Examiner has rejected claims 47-50 under 35 U.S.C. § 112, first paragraph,

asserting that the amendments of September 13, 2006, introduce new matter that was not

described in the specification in such a way as to reasonably convey to one skilled in the

art to that the inventor had possession of the inventions as now claimed. (OA at page 3.)

Applicants respectfully traverse this rejection.

The specification and claims, as originally filed, provide proper descriptive

support for the amendments of September 13, 2006, including the subject matter of

claims 47-50. Presently-pending claims 47-50 are directed to an isolated polynucleotide

comprising a nucleic acid sequence from 83-100% identical to the sequence of SEQ ID

NO: 115, wherein the isolated polynucleotide encodes a toxin capable of binding to a

sodium channel.

Written description does not require that the subject matter of the claim need be

described literally, *i.e.*, using the same terms or *in haec verba*, in order for the disclosure

to satisfy the description requirement. If a skilled artisan would have understood the

inventor to be in possession of the claimed invention at the time of filing, even if every

nuance of the claims is not explicitly described in the specification, then the adequate

description requirement is met. *See, e.g., Vas-Cath, Inc. v Mahurkar*, 935 F.2d 1555 at

1563 (Fed. Cir. 1991); *Martin v. Johnson*, 454 F.2d 746, 751(CCPA 1972) (stating "the

description need not be in *ipsis verbis* [i.e., "in the same words"] to be sufficient"); *see also* MPEP §2163.

Additionally, the "Methodology for Determining Adequacy of Written Description" found at section 2163.II.A.2. of the MPEP provides that, prior to determining whether the disclosure satisfies the written description requirement for the claimed subject matter, an Examiner should review the claims and the *entire specification, including the specific embodiments, figures, and sequence listings*, to understand how the Applicant provides support for the various features of the claimed invention.

In this case, a skilled artisan would have understood the inventor to be in possession of the claimed invention based on the disclosure in the specification and sequence listing as originally filed, which provide descriptive support for the nucleic acid sequences that are at least 95%, 90%, 85% and 83% identical to SEQ ID NO:115. For example, Table 1, column D, on page 3 of the specification discloses a list of 71 nucleic acid sequences[1] that encode isolated scorpion toxins. (specification at page 3). Table 1 and the sequence listing are part of the specification, and should be considered when evaluating the adequacy of the written description.

---

[1] These sequences also appear in the sequence listing as originally filed.

Species	SEQ ID nucleic acid coding region of mature toxin	% identity with SEQ ID 115	SEQ ID primary protein structure of mature toxin	% identity with SEQ ID 116
C. exilicauda	43	86.5 %	44	75%
C. exilicauda	47	87 %	48	76.5%
C. nocius	91	87.7%	92	74.2%
C. elegans	111	82.8%	112	73.3%
C. elegans	**115**	**100%**	**116**	**100%**
C. elegans	119	99.5%	120	95.3%
C. sculpturatus	151	88.5%	152	79.6%
C. sculpturatus	195	88%	196	76.5%

The sequences in the above table are those sequences that share the closest homology with SEQ ID NO:115 as determined by Examiner Desai's sequence search. (*See* APPENDIX A, attached hereto).   The percent homology that each molecule listed in Table 1 has with SEQ ID NO:115 is an inherent feature of each sequence described in the specification. The percent homology between the sequences is a fact based on the structure of the sequences disclosed in the specification and sequence listing. The determination of percent identity between nucleic acid sequences was within the skill of the ordinary artisan as of the filing date of this application.

The sequences listed in the above table are part of the specification as-filed. As shown in the above table, SEQ ID NOs: 43, 47, 91, 111, 119, 151, and 195 share 86.5%, 87%, 87.7%, 82.8%, 99.5%, 88.5%, and 88% sequence identity with SEQ ID NO:115, respectively. Applicants assert that the specification as-filed, including the sequence listing, would have reasonably conveyed to one skilled in the relevant art that the inventors had possession of the claimed nucleic acid sequences having 95%, 90%, 85% or 83% identity with SEQ ID NO:115 at the time the application was filed. Therefore,

the specification provides adequate written description under 35 U.S.C. §112, first

paragraph, for a range of sequences which possess from 83% to 100% sequence

similarity with SEQ ID NO:115, as recited in claims 47-50. Accordingly, this rejection

is believed to have been overcome. Reconsideration and withdrawal of the New Matter

rejection of claims 47-50 is respectfully requested.

> **B.   The specification provides proper written descriptive support for claims 47-50**

The Examiner has rejected claims 47-50 under 35 U.S.C. § 112, first paragraph,

as failing to comply with the written description requirement. More specifically, the

Examiner asserts that the recited subject matter was not described in "the specification in

such a way as to convey to one skilled in the relevant art that the inventor(s), at the time

the application was filed, had possession of the claimed invention." (OA at pages 3-4).

The Examiner also asserts that "[o]ne of skill in the art cannot visualize or recognize

which nucleic acid sequences can be modified and/or mutated such that the

polynucleotide with reduced percent identity retains the function of a toxin affecting

sodium and potassium channel activity as disclosed for SEQ ID NO:115." (OA at pages

3-4). Applicants respectfully traverse this rejection.

The specification as-filed provides adequate written descriptive support for the

nucleic acids recited in claims 47-50, because a person of ordinary skill at the time of

filing could have visualized or recognized the identity of the members of the recited

genus based on recited functional requirements and known structural similarities shared

by polynucleotides that are at least 95%, 90%, 85% and 83% identical to SEQ ID

NO:115. More specifically, the ordinary artisan reading the specification in conjunction

with what was generally known in the art of scorpion toxins would have known that the

sequences that are at least 95%, 90%, 85% or 83% identical to SEQ ID NO:115 would

need to bind to the Na$^+$ channel and possess four cysteine bonds to fall within the scope

of claims 47-50.

An objective standard for determining compliance with the written description

requirement of 35 U.S.C. §112, first paragraph, is, "does the description clearly allow

persons of ordinary skill in the art to recognize that he or she invented what is claimed?"

In re Gosteli, 872 F.2d 1008, 1012 (Fed. Cir. 1989), *see also* MPEP 2163.02. An

applicant may show possession of the claimed invention by describing the claimed

invention with all of its limitations using such descriptive means as words, structures,

figures, diagrams, and formulas that fully set forth the claimed invention. *See Lockwood*

v. American Airlines, Inc., 107 F.3d 1565, 1572 (Fed. Cir. 1997). Moreover, the

disclosure of a species has also been found to be sufficient to support a claimed genus

when the disclosure of species would lead a person of ordinary skill to the genus. *See In*

re Herschler, 591 F.2d 693 (CCPA 1979); *see also* MPEP 2163.05.). In *Herschler,* the

Court held that the disclosure of one corticosteroid was sufficient to support

"physiologically active steroid" because the use would lead one of ordinary skill to the

entire class of compounds. 591 F.2d at 697. The Federal Circuit has held that when

generic elements of a claim are so well known and thoroughly characterized in the art

that their recitation alone is sufficient to convey distinguishing information regarding

their identity, the written description requirement for those elements is fully satisfied.

See Amgen Inc. v. Hoechst Marion Roussel Inc., 65 U.S.P.Q.2d 1385, 1398 (Fed. Cir.

2003). Another important consideration in assessing written description of a claimed

invention is the knowledge of one skilled in the art. *See Bilstad v. Wakalopulos*, 386

F.3d 1116, 1126 (Fed. Cir. 2004).

(i)   The encoded toxins of claims 47-50 must be capable of binding to Na+ channels

In this case, claims 47-50 have been amended to recite an isolated

polynucleotide comprising a nucleic acid sequence from 83-100% identical to the

sequence of SEQ ID NO: 115, wherein the isolated polynucleotide encodes a toxin

capable of binding to a sodium channel. As discussed above, the specification as-filed,

including the sequence listing, provides proper written descriptive support under 35

U.S.C. §112, first paragraph, for polynucleotides that are at least 95%, 90%, 85% and

83% identical to SEQ ID NO:115, as recited in claims 47-50. Furthermore, all of the

publications cited in the specification have been incorporated by reference in their

entirety, and thereby provide additional descriptive support for the presently pending

claims. (specification paragraph [0105]).

Applicants explain in the specification that scorpion toxins generally fall into two

categories: the long chain toxins, 60-76 amino acids in length, which block the Na^+

channel in excitable cells; and the short chain toxins, 29-41 amino acids in length that

affect K^+ channels. (specification paragraph [0004]). The claimed toxins are all Na^+

channel toxins, 60-76 amino acids in length, and they all bind to the membrane bound

sodium channel. (specification paragraph [0005]). It is the binding of the toxin to the

cation channel (the Na^+ channel) that causes most of the toxicological symptoms in a

patient. (specification paragraph [0009]; *see also*, Dehesa-Davilla, page 225).

The specification describes isolated and purified scorpion toxin nucleic acid sequences in the sequence listing, as well as in Table 1. The ordinary artisan reading the specification in light of what was known in the art would have recognized that the claimed sequences fall into the genus of long chain Na^+ channel blocking toxins. (*See* specification paragraph [0004]). Thus, the ordinary artisan as of the filing date would have understood that claims drawn to SEQ ID NO:115 or sequences having 95%, 90%, 85% and 83% sequence identity with SEQ ID NO: 115 are directed to Na^+ channel blocking toxins.

<blockquote>(ii)   The encoded toxins of claims 47-50 posses a common structural motif</blockquote>

The Na^+ channel toxins from scorpions also possess a common structural motif. Applicants explain in the specification that these Na^+ channel affecting scorpion toxins posses eight cysteine residues which form four cysteine bonds in the mature toxin. (specification paragraph [0004]; *see also Possani et al.* at page 290, column 2). The common structural motif consists of one stretch of α helix plus three strands of β sheet in antiparallel arrangement, connected by variable regions forming loops. (specification paragraph [0004]; *see also* Possani *et al.* p 287, 290). The cysteine residues are numbered consecutively 1-8 from the N- to the C- terminal of the toxin. Cysteine residues 1 and 8, 2 and 5, 3 and 6, as well as residues 4 and 7 form the four disulfide bridges. These disulfide bonds are conserved in all of the Na^+ channel blocking scorpion toxins that were known as of the filing date of the presently-pending application, including the sequences disclosed in the specification. (specification paragraph [0004]; *see also* Possani *et al.* p 290, column 2; *see also* APPENDIX B attached hereto, which

shows a sequence alignment of the sodium channel toxins disclosed in the specification,

and highlights the conserved cysteine residues). In fact, as of the filing date of the

present application, all Na^+ channel-specific toxins were known to be stabilized by four

disulfide bridges. (specification paragraph [0004]; *see also* Possani *et al.* p 287). Thus,

the ordinary artisan reading the specification in light of what was known in the art would

have recognized and understood that the recited sequences having 95%, 90%, 85% and

83% sequence identity with SEQ ID NO: 115 would also possess the conserved

structural motif of four cysteine bonds.

Based on the combination of what was known in the art about scorpion toxins at

the time of filing and the disclosure of seven species of nucleic acid that fall within the

scope of claims 47-50, the specification conveys to one of ordinary skill in the art that

the recited polynucleotides fall into the genus of long chain Na^+ channel-blocking toxins

possessing a conserved structural motif of four cysteine bonds.

<div style="text-align:center;">

**(iii)   The USPTO's Written Description Guidelines
Support a Finding of Proper Written Descriptive Support for
Claims 47-50**

</div>

The USPTO's "*Revised Interim Written Description Guidelines Training*

Materials" (hereinafter, "*Guidelines*") provides 18 examples describing how to

determine whether the written description requirement of 35 U.S.C. §112, paragraph 1, is

satisfied. The facts set forth in Example 14 are almost identical to the present situation,

and support a finding of proper written descriptive support for presently-pending claims

47-50.

First, the language of claims 47-50 is extremely similar in form and substance to

that of the sample claim provided in Example 14, which recites:

> A protein having SEQ ID NO: 3 and variants thereof that are at least 95%
> identical to SEQ ID NO: 3 and catalyze the reaction of A→ B.

Guidelines, p. 53. Similarly, claims 47-50 require that the claimed polynucleotide is at

least 83% identical to SEQ ID NO:115 (the reference compound) and encodes a toxin

that is capable of binding to a sodium channel, which is an essential feature of the

claimed invention. Thus, the first requirement of Example 14 is met.

Second, the *Guidelines* state that a search of the prior art indicated that

exemplified SEQ ID NO: 3 was novel and unobvious. *Id.* at page 54. In the present

case, the Examiner stated in the Office Action of October 24, 2006, that the prior art does

not describe an isolated nucleic acid comprising SEQ ID NO: 115, which is recited in

claims 47-50. (OA at page 4). Thus, the second requirement set forth in Example 14 has

been satisfied with regard to currently pending claims 47-50.

Third, an actual reduction to practice of a single disclosed species was deemed

sufficient to support the recited genus of proteins that must be variants of exemplified

SEQ ID NO: 3. *See Guidelines*, p. 54. The *Guidelines* state that the actual reduction to

practice one species was sufficient because all of the variants were required to possess

the specific functional activity and had a high percent structural identity with the

reference compound. *See Guidelines*, p. 54. In the present case, Applicants have shown

possession of the claimed invention by a reduction to practice as evidenced by the

descriptive support for at least seven sequences that fall within the scope of the claims,

as well as support for the functional element of the claims. (*See* specification, Table 1,

and the sequence listing). Thus, the third requirement set forth in Example 14 of the

Guidelines has been satisfied.

Fourth, procedures for making variants of exemplified SEQ ID NO:3 which have

95% identity to SEQ ID NO:3 and retain its activity were conventional in the art. *See*

Guidelines, p. 53. In the present case, methods for making variants that are at least 83%

identical to the reference compound were known in the art at the time of filing, and are

described in our specification. (*See Molecular Cloning: A Laboratory Manual* (2nd ed.),

Sambrook *et al.* (Cold Spring Harbor Lab. Press, 1989), chapters 15-18; *see also*

specification [0040]). Thus, the fourth requirement set forth in Example 14 of the

Guidelines has been satisfied with regard to presently pending claims 47-50.

Fifth, an assay was described in the specification that identified the other proteins

having the binding activity recited in the example claim. *See Guidelines*, p. 53. In the

present case, the toxins that are at least 95%, 90%, 85% or 83% identical to SEQ ID

NO:115 can easily be tested for their binding to the Na^{+} channel. (specification

paragraph [0005]; *see also* Couraud *et al.* p10-12.] Although there are many different

ways to test the binding of a toxin to a Na^{+} channel, one test described in the

specification through an incorporated reference uses a rat synaptosome and a labeled

toxin. (specification paragraph [0005]; *see also* Couraud *et al.* p10-12). Thus, the fifth

requirement set forth in Example 14 of the *Guidelines* has been satisfied with regard to

presently pending claims 47-50.

Based on the requirements set forth in Example 14 of the USPTO's *Revised*

Interim Written Description Guidelines Training Materials, as well as the common

structural motifs and functional requirements, the specification conveys to a person of

ordinary skill in the art that the inventors had possession of, and broadly described, an

isolated polynucleotide comprising a nucleic acid sequence from 83-100% identical to

SEQ ID NO:155, wherein the isolated polynucleotide encodes a toxin that is capable of

binding to a sodium channel. Thus, the specification provides adequate written

description under 35 U.S.C. §112, first paragraph, for an isolated polynucleotide as

recited in presently-amended independent claims 47-50, as well as those claims which

depend therefrom. Accordingly, this rejection is believed to have been overcome.

Reconsideration and withdrawal of the rejection of claims 47-50 is respectfully

requested.

Conclusion

The Examiner has indicated that claim 3 directed to SEQ ID NO: 115 is

allowable.

All of the stated grounds of objection and rejection have been properly traversed,

accommodated, or rendered moot. Applicants therefore respectfully request that the

Examiner reconsider all presently outstanding objections and rejections and that they be

withdrawn. Applicants believe that a full and complete reply has been made to the

outstanding Office Action and, as such, the present application is in condition for

allowance. If the Examiner believes, for any reason, that personal communication will

expedite prosecution of this application, the Examiner is invited to telephone the

undersigned at the number provided.

Prompt and favorable consideration of this Amendment and Reply is respectfully requested.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Laura A. Vogel
Attorney for Applicants
Registration No. 55,702

Date: January 24, 2007

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600
623951_1.DOC

```
                    GenCore version 5.1.6
         Copyright (c) 1993 - 2006 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on:          January 21, 2006, 21:31:18 ; Search time 2178 seconds
                                  (without alignments)
                                  728.981 Million cell updates/sec

Title:           US-10-721-793-115
Perfect Score:   192
Sequence:        1 aaagacggttacctggtgga.........ccctttctaataaaagatgc 192

Scoring table:   IDENTITY_NUC
                 Gapop 10.0 , Gapext 1.0

Searched:        9793542 seqs, 413689005 residues

Total number of hits satisfying chosen parameters:    19587084

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
                 Maximum Match 100%
                 Listing first 45 summaries

Database :       Published Applications NA Main:*
                 1: /cgm2_6/pcdata/1/pubpna/US07_PUBCOMB.seq:*
                 2: /cgm2_6/pcdata/1/pubpna/US08_PUBCOMB.seq:*
                 3: /cgm2_6/pcdata/1/pubpna/US09A_PUBCOMB.seq:*
                 4: /cgm2_6/pcdata/1/pubpna/US09B_PUBCOMB.seq:*
                 5: /cgm2_6/pcdata/1/pubpna/US10A_PUBCOMB.seq:*
                 6: /cgm2_6/pcdata/1/pubpna/US10B_PUBCOMB.seq:*
                 7: /cgm2_6/pcdata/1/pubpna/US10C_PUBCOMB.seq:*
                 8: /cgm2_6/pcdata/1/pubpna/US10D_PUBCOMB.seq:*
                 9: /cgm2_6/pcdata/1/pubpna/US10E_PUBCOMB.seq:*
                10: /cgm2_6/pcdata/1/pubpna/US11_PUBCOMB.seq:*
```

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Match Length	DB	ID	Description
1	192	100.0	192	9	US-10-721-793-115	Sequence 115, App
2	192	100.0	323	9	US-10-721-793-113	Sequence 113, App
3	190.4	99.2	192	9	US-10-721-793-119	Sequence 119, App
4	190.4	99.2	323	9	US-10-721-793-117	Sequence 117, App
5	156.8	81.7	192	9	US-10-721-793-151	Sequence 151, App
6	156.8	81.7	320	9	US-10-721-793-149	Sequence 149, App
7	155.2	80.8	192	9	US-10-721-793-195	Sequence 195, App
8	155.2	80.8	320	9	US-10-721-793-193	Sequence 193, App
9	152	79.2	192	9	US-10-721-793-47	Sequence 47, Appl
10	152	79.2	258	9	US-10-721-793-45	Sequence 45, Appl
11	150.4	78.3	192	9	US-10-721-793-43	Sequence 43, Appl
12	150.4	78.3	254	9	US-10-721-793-41	Sequence 41, Appl
13	145.4	75.7	198	9	US-10-721-793-91	Sequence 91, Appl
14	145.4	75.7	323	9	US-10-721-793-89	Sequence 89, Appl
15	126.8	66.0	189	9	US-10-721-793-111	Sequence 111, App
16	126.8	66.0	311	9	US-10-721-793-109	Sequence 109, App
17	124.6	64.9	323	9	US-10-721-793-101	Sequence 101, App
18	124.6	64.9	323	9	US-10-721-793-105	Sequence 105, App
19	123.2	64.2	192	9	US-10-721-793-103	Sequence 103, App
20	123.2	64.2	192	9	US-10-721-793-107	Sequence 107, App
21	123	64.1	195	9	US-10-721-793-147	Sequence 147, App
22	123	64.1	198	9	US-10-721-793-175	Sequence 175, App
23	123	64.1	323	9	US-10-721-793-145	Sequence 145, App

24	123	64.1	323	9	US-10-721-793-173	Sequence 173, App
25	119.8	62.4	198	9	US-10-721-793-67	Sequence 67, Appl
26	119.8	62.4	198	9	US-10-721-793-71	Sequence 71, Appl
27	119.8	62.4	198	9	US-10-721-793-159	Sequence 159, App
28	119.8	62.4	198	9	US-10-721-793-163	Sequence 163, App
29	119.8	62.4	322	9	US-10-721-793-65	Sequence 65, Appl
30	119.8	62.4	322	9	US-10-721-793-69	Sequence 69, Appl
31	119.8	62.4	323	9	US-10-721-793-157	Sequence 157, App
32	119.8	62.4	323	9	US-10-721-793-161	Sequence 161, App
33	118.2	61.6	195	9	US-10-721-793-139	Sequence 139, App
34	118.2	61.6	198	9	US-10-721-793-155	Sequence 155, App
35	118.2	61.6	319	9	US-10-721-793-153	Sequence 153, App
36	118.2	61.6	323	9	US-10-721-793-137	Sequence 137, App
37	116.6	60.7	195	9	US-10-721-793-83	Sequence 83, Appl
38	116.6	60.7	274	9	US-10-721-793-81	Sequence 81, Appl
39	116.6	60.7	323	9	US-10-721-793-97	Sequence 97, Appl
40	115	59.9	195	9	US-10-721-793-167	Sequence 167, App
41	115	59.9	195	9	US-10-721-793-171	Sequence 171, App
42	115	59.9	323	9	US-10-721-793-165	Sequence 165, App
43	115	59.9	323	9	US-10-721-793-169	Sequence 169, App
44	113.4	59.1	195	9	US-10-721-793-23	Sequence 23, Appl
45	113.4	59.1	195	9	US-10-721-793-143	Sequence 143, App

ALIGNMENTS

```
RESULT 1
US-10-721-793-115
; Sequence 115, Application US/10721793
; Publication No. US2005006533lA1
; GENERAL INFORMATION:
;  APPLICANT: Corona Villegas, Miguel
;  APPLICANT: Garcia Rodriguez, Ma Consuelo
;  APPLICANT: Valdez Cruz, Norma Adriana
;  APPLICANT: Gurrola Briones, Georgina
;  APPLICANT: Becerril Lujan, Baltazar
;  APPLICANT: Possani Postay, Lourival Domingos
;  TITLE OF INVENTION: Recombinant Immunogens for the Generation of Antivenoms to the
;  TITLE OF INVENTION: Venom of Scorpions of the Genus Centruroides
;  FILE REFERENCE: 2099.0070001
;  CURRENT APPLICATION NUMBER: US/10/721,793
;  CURRENT FILING DATE: 2003-11-26
;  PRIOR APPLICATION NUMBER: US 60/430,067
;  PRIOR FILING DATE: 2002-12-02
;  NUMBER OF SEQ ID NOS: 294
;  SOFTWARE: Patentin version 3.1
; SEQ ID NO 115
; LENGTH: 192
; TYPE: DNA
; ORGANISM: Centruroides elegans
; FEATURE:
;  NAME/KEY: CDS
;  LOCATION: (1)..(192)
;  OTHER INFORMATION: Product= Sodium-channel modifier toxin
US-10-721-793-115

Query Match             100.0%;  Score 192;  DB 9;  Length 192;
Best Local Similarity   100.0%;  Pred. No. 1.1e-53;
Matches  192;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy    1 AAAGACGGTTATCTGGTGGACAAGACGGCTGCAAATACACTTGCTGGATATTGGGAGAA 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1 AAAGACGGTTATCTGGTGGACAAGACGGCTGCAAATACACTTGCTGGATATTGGGAGAA 60

Qy   61 AACRAATACTGCAATAGGGAATGCACATGGAAGCACCGAGGAGGTAATTACGGCTATTGC 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   61 AACAAATACTGCAATAGGGAATGCACATGGAAGCACCGAGGAGGTAATTACGGCTATTGC 120

Qy  121 TACGGATTTGGGTGCTATTGCGGAAGGATTGTCCGATAGTACACCGACTTGGCCCCTTTCT 180
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  121 TACGGATTTGGGTGCTATTGCGGAAGGATTGTCCGATAGTACACCGACTTGGCCCCTTTCT 180
```

```
Qy    181 AATAAAGATGC 192
          ||||||||||
Db    181 AATAAAGATGC 192

RESULT 2
US-10-721-793-113
; Sequence 113, Application US/10721793
; Publication No. US20050065331A1
; GENERAL INFORMATION:
;   APPLICANT: Corona Villegas, Miguel
;   APPLICANT: Garcia Rodriguez, Ma Consuelo
;   APPLICANT: Valdez Cruz, Norma Adriana
;   APPLICANT: Gurrola Briones, Georgina
;   APPLICANT: Becerril Lujan, Baltazar
;   APPLICANT: Possani Postay, Lourival Domingos
;   TITLE OF INVENTION: Recombinant Immunogens for the Generation of Antivenoms to the
;   TITLE OF INVENTION: Venom of Scorpions of the Genus Centruroides
;   FILE REFERENCE: 2099.0070001
;   CURRENT APPLICATION NUMBER: US/10/721,793
;   CURRENT FILING DATE: 2003-11-26
;   PRIOR APPLICATION NUMBER: US 60/430,067
;   PRIOR FILING DATE: 2002-12-02
;   NUMBER OF SEQ ID NOS: 294
;   SOFTWARE: Patentin version 3.1
; SEQ ID NO 113
;   LENGTH: 323
;   TYPE: DNA
;   ORGANISM: Centruroides elegans
;   FEATURE:
;   NAME/KEY: CDS
;   LOCATION: (5)..(265)
;   OTHER INFORMATION: Product= Sodium-channel modifier toxin precursor
;   OTHER INFORMATION: In the mature peptide, the last Cys is amidated, and the last Gly
;   OTHER INFORMATION: and the last 2 basic aminoacids are cut
;   FEATURE:
;   NAME/KEY: 3'UTR
;   LOCATION: (269)..(323)
;   OTHER INFORMATION:
;   FEATURE:
;   NAME/KEY: 5'UTR
;   LOCATION: (1)..(4)
;   OTHER INFORMATION:
;   FEATURE:
;   NAME/KEY: mat_peptide
;   LOCATION: (65)..()
;   OTHER INFORMATION: Product= Sodium-channel modifier toxin
;   FEATURE:
;   NAME/KEY: sig_peptide
;   LOCATION: (5)..(64)
;   OTHER INFORMATION:
US-10-721-793-113

Query Match             100.0%;  Score 192; DB 9; Length 323;
Best Local Similarity   100.0%;  Pred. No. 1.3e-53;
Matches 192; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy    1 AAAGACGGTTATCTGGTGGACAAGACGGGCTGCAAATACACTTGCTGGATATTGGGAGAA 60
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   65 AAAGACGGTTATCTGGTGGACAAGACGGGCTGCAAATACACTTGCTGGATATTGGGAGAA 124

Qy   61 AACAAATACTGCAATAGGGAATGCACATGGAAGCACCGAGGAGGTAATTACGGCTATTGC 120
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  125 AACAAATACTGCAATAGGGAATGCACATGGAAGCACCGAGGAGGTAATTACGGCTATTGC 184

Qy  121 TACGGATTTGGGTGCTATTGCGAAGGATTGTCCGATAGTACACCGACTTGGCCCCTTTCT 180
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  185 TACGGATTTGGGTGCTATTGCGAAGGATTGTCCGATAGTACACCGACTTGGCCCCTTTCT 244

Qy  181 AATAAAGATGC 192
        |||||||||||
Db  245 AATAAAGATGC 256
```

```
RESULT 3
US-10-721-793-119
; Sequence 119, Application US/10721793
; Publication No. US20050065331A1
; GENERAL INFORMATION:
;   APPLICANT: Corona Villegas, Miguel
;   APPLICANT: Garcia Rodriguez, Ma Consuelo
;   APPLICANT: Valdez Cruz, Norma Adriana
;   APPLICANT: Gurrola Briones, Georgina
;   APPLICANT: Becerril Lujan, Baltazar
;   APPLICANT: Possani Postay, Lourival Domingos
;   TITLE OF INVENTION: Recombinant Immunogens for the Generation of Antivenoms to the
;   TITLE OF INVENTION: Venom of Scorpions of the Genus Centruroides
;   FILE REFERENCE: 2099.0070001
;   CURRENT APPLICATION NUMBER: US/10/721,793
;   CURRENT FILING DATE: 2003-11-26
;   PRIOR APPLICATION NUMBER: US 60/430,067
;   PRIOR FILING DATE: 2002-12-02
;   NUMBER OF SEQ ID NOS: 294
;   SOFTWARE: Patentin version 3.1
; SEQ ID NO 119
;   LENGTH: 192
;   TYPE: DNA
;   ORGANISM: Centruroides elegans
;   FEATURE:
;   NAME/KEY: CDS
;   LOCATION: (1)..(192)
;   OTHER INFORMATION: Product= Sodium-channel modifier toxin
US-10-721-793-119

Query Match             99.2%;  Score 190.4; DB 9; Length 192;
Best Local Similarity   99.5%;  Pred. No. 3.6e-53;
Matches 191; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy    1 AAAGACGGTTATCTGGTGGACAAGACGGGCTGCAAATACACTTGCTGGATATTGGGAGAA 60
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1 AAAGACGGTTATCTGGTGGACAAGACGGGCTGCAAATACACTTGCTGGATATTGGGAGAA 60

Qy   61 AACAAATACTGCAATAGGGAATGCACATGGAAGCACCGAGGAGGTAATTACGGCTATTGC 120
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   61 AACAAATACTGCAATAGGGAATGCACATGGAAGCACCGAGGAGGTAATTACGGCTATTGC 120

Qy  121 TACGGATTTGGGTGCTATTGCGAAGGATTGTCCGATAGTACACCGACTTGGCCCCTTTCT 180
        |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  121 TACGGATTTGGGTGCTATTGCGAAGGATTGTCCGATAGTACACCGACTTGGCCCCCTTCCT 180

Qy  181 AATAAAGATGC 192
        |||||||||||
Db  181 AATAAAGATGC 192

RESULT 4
US-10-721-793-117
; Sequence 117, Application US/10721793
; Publication No. US20050065331A1
; GENERAL INFORMATION:
;   APPLICANT: Corona Villegas, Miguel
;   APPLICANT: Garcia Rodriguez, Ma Consuelo
;   APPLICANT: Valdez Cruz, Norma Adriana
;   APPLICANT: Gurrola Briones, Georgina
;   APPLICANT: Becerril Lujan, Baltazar
;   APPLICANT: Possani Postay, Lourival Domingos
;   TITLE OF INVENTION: Recombinant Immunogens for the Generation of Antivenoms to the
;   TITLE OF INVENTION: Venom of Scorpions of the Genus Centruroides
;   FILE REFERENCE: 2099.0070001
;   CURRENT APPLICATION NUMBER: US/10/721,793
;   CURRENT FILING DATE: 2003-11-26
;   PRIOR APPLICATION NUMBER: US 60/430,067
;   PRIOR FILING DATE: 2002-12-02
;   NUMBER OF SEQ ID NOS: 294
;   SOFTWARE: Patentin version 3.1
; SEQ ID NO 117
```

LENGTH: 323
TYPE: DNA
ORGANISM: Centruroides elegans
FEATURE:
NAME/KEY: CDS
LOCATION: (5)..(265)
OTHER INFORMATION: Product= Sodium-channel modifier toxin precursor
OTHER INFORMATION: In the mature peptide, the last Cys is amidated, and the last Gly
OTHER INFORMATION: and the last 2 basic aminoacids are cut
FEATURE:
NAME/KEY: 3'UTR
LOCATION: (269)..(323)
OTHER INFORMATION:
FEATURE:
NAME/KEY: 5'UTR
LOCATION: (1)..(4)
OTHER INFORMATION:
FEATURE:
NAME/KEY: mat_peptide
LOCATION: (65)..()
OTHER INFORMATION: Product= Sodium-channel modifier toxin
FEATURE:
NAME/KEY: sig_peptide
LOCATION: (5)..(64)
OTHER INFORMATION:
US-10-721-793-117

Query Match   99.2%;   Score 190.4; DB 9; Length 323;
Best Local Similarity 99.5%;   Pred. No. 4.5e-53;
Matches 191; Conservative 0; Mismatches 0; Indels 1; Gaps 0;

Qy   1 AAAGACGGTTATCTGGTGGACAAGACGGGCTGCAAATACACTTGCTGGATATTGGGAGAA 60
         ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   65 AAAGACGGTTATCTGGTGGACAAGACGGGCTGCAAATACACTTGCTGGATATTGGGAGAA 124

Qy   61 AACAAATACTGCAATAGGGAATGCACATGGAAGCACCGAGGAGGTAATTACCGGCTATTGC 120
         ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 125 AACAAATACTGCAATAGGGAATGCACATGGAAGCACCGAGGAGGTAATTACCGGCTATTGC 184

Qy 121 TACGGATTTGGGTGCTATTGCGAAGGATTGTCCGATAGTACCACCGGCCCCTTTCT 180
         ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 185 TACGGATTTGGGTGCTATTGCGAAGGATTGTCCGATAGTACCACCGGCCCCTTTCCT 244

Qy 181 AATAAAGATGC 192
         |||||||||||
Db 245 AATAAAGATGC 256

RESULT 5
US-10-721-793-151
; Sequence 151, Application US/10721793
; Publication No. US20050065331A1
GENERAL INFORMATION:
APPLICANT: Corona Villegas, Miguel
APPLICANT: Garcia Rodriguez, Ma Consuelo
APPLICANT: Valdez Cruz, Norma Adriana
APPLICANT: Gurrola Briones, Georgina
APPLICANT: Becerril Lujan, Baltazar
APPLICANT: Possani Postay, Lourival Domingos
TITLE OF INVENTION: Recombinant Immunogens for the Generation of Antivenoms to the
TITLE OF INVENTION: Venom of Scorpions of the Genus Centruroides
FILE REFERENCE: 2099.0070001
CURRENT APPLICATION NUMBER: US/10/721,793
CURRENT FILING DATE: 2003-11-26
PRIOR APPLICATION NUMBER: US 60/430,067
PRIOR FILING DATE: 2002-12-02
NUMBER OF SEQ ID NOS: 294
SOFTWARE: PatentIn version 3.1
SEQ ID NO 151
LENGTH: 192
TYPE: DNA
ORGANISM: Centruroides sculpturatus
FEATURE:

NAME/KEY: CDS
LOCATION: (1)..(192)
OTHER INFORMATION: Product= Sodium-channel modifier toxin
PUBLICATION INFORMATION:
AUTHORS: Corona, M., Valdez-Cruz, N.A., Merino, E., Zurita, M. & Possani L.D.
TITLE: Genes and peptides from the scorpion Centruroides sculpturatus Ewing.
JOURNAL: Toxicon
VOLUME: 39
ISSUE: 12
PAGES: 1893-1898
DATE: 2001-12-01
DATABASE ENTRY DATE:
RELEVANT RESIDUES: (1)..(192)
US-10-721-793-151

Query Match   81.7%;   Score 156.8; DB 9; Length 192;
Best Local Similarity 88.5%;   Pred. No. 6.1e-42;
Matches 170; Conservative 0; Mismatches 22; Indels 0; Gaps 0;

Qy   1 AAAGACGGTTATCTGGTGGACAAGACGGGCTGCAAATACACTTGCTGGATATTGGGAGAA 60
         ||||||||||||||||| ||||| |||||| ||||||| || |||||||||||||||||
Db   1 AAGGACGGTTATCTCAGTGGAAAAAGACGGGCTGCAAAAAGACTTGCTACAAATTGGGAGAA 60

Qy   61 AACAAATACTGCAATAGGGAATGCACATGGAAGCACCGAGGAGGTAATTACCGGCTATTGC 120
         |||||||| |||||||||||||| |||||| |||| |||||| || |||||||||||||
Db   61 AACAAATACTGCAATAGGGAATGCAAATGGAAGCACATAGGAGGAGTTATTGGCTATTTC 120

Qy 121 TACGGATTTGGGTGCTATTGCGAAGGATTGTCCGATAGTACCACCGGCCCCTTTCT 180
         ||||||||||||||||||||||||||||| ||||||||| ||| ||||||||||||
Db 121 TACGGATTTGGGTGCTATTGCGAAGGATTGTCCGATAGTACAGAGACTTGGCCCCTTTCCT 180

Qy 181 AATAAAGATGC 192
         ||||| |||||
Db 181 AATAAACATGC 192

RESULT 6
US-10-721-793-149
; Sequence 149, Application US/10721793
; Publication No US2005006531A1
GENERAL INFORMATION:
APPLICANT: Corona Villegas, Miguel
APPLICANT: Garcia Rodriguez, Ma Consuelo
APPLICANT: Valdez Cruz, Norma Adriana
APPLICANT: Gurrola Briones, Georgina
APPLICANT: Becerril Lujan, Baltazar
APPLICANT: Possani Postay, Lourival Domingos
TITLE OF INVENTION: Recombinant Immunogens for the Generation of Antivenoms to the
TITLE OF INVENTION: Venom of Scorpions of the Genus Centruroides
FILE REFERENCE: 2099.0070001
CURRENT APPLICATION NUMBER: US/10/721,793
CURRENT FILING DATE: 2003-11-26
PRIOR APPLICATION NUMBER: US 60/430,067
PRIOR FILING DATE: 2002-12-02
NUMBER OF SEQ ID NOS: 294
SOFTWARE: PatentIn version 3.1
SEQ ID NO 149
LENGTH: 320
TYPE: DNA
ORGANISM: Centruroides sculpturatus
FEATURE:
NAME/KEY: CDS
LOCATION: (5)..(262)
OTHER INFORMATION: Product= Sodium-channel modifier toxin precursor
OTHER INFORMATION: In the mature peptide, the last Cys is amidated, and the last Gl
OTHER INFORMATION: and the last 2 basic aminoacids are cut
FEATURE:
NAME/KEY: mat_peptide
LOCATION: (62)..()
OTHER INFORMATION: Product= Sodium-channel modifier toxin
FEATURE:
NAME/KEY: sig_peptide

; LOCATION: (5)..(61)
; OTHER INFORMATION:
; FEATURE:
; NAME/KEY: 3'UTR
; LOCATION: (266)..(320)
; OTHER INFORMATION:
; FEATURE:
; NAME/KEY: 5'UTR
; LOCATION: (1)..(4)
; OTHER INFORMATION:
; PUBLICATION INFORMATION:
; AUTHORS: Corona, M., Valdez-Cruz, N.A., Merino, E., Zurita, M. & Possani L.D.
; TITLE: Genes and peptides from the scorpion Centruroides sculpturatus Ewing,
; TITLE: that recognize Na+-channels
; JOURNAL: Toxicon
; VOLUME: 39
; ISSUE: 12
; PAGES: 1893-1898
; DATE: 2001-12-01
; DATABASE ENTRY DATE:
; RELEVANT RESIDUES: (5)..(262)
US-10-721-793-149

Query Match   81.7%;   Score 156.8; DB 9; Length 320;
Best Local Similarity   88.5%;   Pred. No. 7.6e-42;
Matches 170; Conservative   0; Mismatches 22; Indels   0; Gaps   0;

Qy   1 AAAGACGGTTATCTGGTGGACAAGACGGGCTGCAAATACACTTGCTGGATATTGGGAGAA 60
       || |||||||||| ||||||||| ||||||||||| | |||||| || ||||||||||||
Db   62 AAGGACCGTTATCTAGTGGAAAAGACGGGCTGCAAAAAGACTTGCTACAAATTGGGAGAA 121

Qy   61 AACAAATACTGCAATAGGGAATGCACATAGGAAGCACCGAGGAGGTAATTACGGCTATTGC 120
       |||| | ||||||||| ||||||||||||||| |||||||| || ||||||||||||||||
Db   122 AACGATTTTTGCAATAGGGAATGCAAATGGAAGCACATAGGAGGTAGTTATGGCTATTTC 181

Qy   121 TACGGATTTGGGTGCTATTGCGAAGGATTGTCCGATAGTACACCGACTTGGCCCCTTTCT 180
       |||||||||||| |||||||| ||||||| | ||||||||||| ||||| |||||||| ||
Db   182 TACGGATTTGGGTGCTATTGCGAAGGATTGCCCGATAGTAGTACACAGACTTGGCCCCTTCCT 241

Qy   181 AATAAAAGATGC 192
       ||||| |||||
Db   242 AATAAAACATGC 253

RESULT 7
US-10-721-793-195
; Sequence 195, Application US/10721793
; Publication No. US20050065331A1
; GENERAL INFORMATION:
; APPLICANT: Corona Villegas, Miguel
; APPLICANT: Garcia Rodriguez, Ma Consuelo
; APPLICANT: Valdez Cruz, Norma Adriana
; APPLICANT: Gurrola Briones, Georgina
; APPLICANT: Becerril Lujan, Baltazar
; APPLICANT: Possani Postay, Lourival Domingos
; TITLE OF INVENTION: Recombinant Immunogens for the Generation of Antivenoms to the
; TITLE OF INVENTION: Venom of Scorpions of the Genus Centruroides
; FILE REFERENCE: 2099.0070001
; CURRENT APPLICATION NUMBER: US/10/721,793
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 60/430,067
; PRIOR FILING DATE: 2002-12-02
; NUMBER OF SEQ ID NOS: 294
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 195
; LENGTH: 192
; TYPE: DNA
; ORGANISM: Centruroides sculpturatus
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (1)..(192)
; OTHER INFORMATION: Product= Sodium-channel modifier toxin
; PUBLICATION INFORMATION:

; AUTHORS: Corona, M., Valdez-Cruz, N.A., Merino, E., Zurita, M. & Possani L.D.
; TITLE: Genes and peptides from the scorpion Centruroides sculpturatus Ewing,
; TITLE: that recognize Na+-channels
; JOURNAL: Toxicon
; VOLUME: 39
; ISSUE: 12
; PAGES: 1893-1898
; DATE: 2001-12-01
; DATABASE ENTRY DATE:
; RELEVANT RESIDUES: (1)..(192)
US-10-721-793-195

Query Match   80.8%;   Score 155.2; DB 9; Length 192;
Best Local Similarity   88.0%;   Pred. No. 2.1e-41;
Matches 169; Conservative   0; Mismatches 23; Indels   0; Gaps   0;

Qy   1 AAAGACGGTTATCTGGTGGACAAGACGGGCTGCAAATACACTTGCTGGATATTGGGAGAA 60
       || |||||||||| ||||||||| ||||||||||| | |||||| || ||||||||||||
Db   1 AAGGAAGGTTATCTGGTGGACGTAAAGGGCTGCAAAAAAAAATTGCTGGAAATTGGGAGAT 60

Qy   61 AACAAATACTGCAATAGGGAATGCACATGGAAGCACCGAGGAGGTAATTACGGCTATTGC 120
       |||| | |||||||||||||||||||||| ||| |||||||||| ||||||||||||||||
Db   61 AACGATTATTGCAATAGGGAATGTAAATGGAAGCACATAGGAGTAGTTACGGCTATTGC 120

Qy   121 TACGGATTTGGGTGCTATTGCGAAGGATTGTCCGATAGTACACCGACTTGGCCCCTTTCT 180
       |||||||||||| |||||||| ||||||| | ||||||||||| ||||| |||||||| ||
Db   121 TACGGATTTGGGTGCTATTGCGAAGGATTGCCCGATAGTAGTACACAGACTTGGCCCCTTCCT 180

Qy   181 AATAAAAGATGC 192
       ||||| ||||||
Db   181 AATAAAACATGC 192

RESULT 8
US-10-721-793-193
; Sequence 193, Application US/10721793
; Publication No. US20050065331A1
; GENERAL INFORMATION:
; APPLICANT: Corona Villegas, Miguel
; APPLICANT: Garcia Rodriguez, Ma Consuelo
; APPLICANT: Valdez Cruz, Norma Adriana
; APPLICANT: Gurrola Briones, Georgina
; APPLICANT: Becerril Lujan, Baltazar
; APPLICANT: Possani Postay, Lourival Domingos
; TITLE OF INVENTION: Recombinant Immunogens for the Generation of Antivenoms to the
; TITLE OF INVENTION: Venom of Scorpions of the Genus Centruroides
; FILE REFERENCE: 2099.0070001
; CURRENT APPLICATION NUMBER: US/10/721,793
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 60/430,067
; PRIOR FILING DATE: 2002-12-02
; NUMBER OF SEQ ID NOS: 294
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 193
; LENGTH: 320
; TYPE: DNA
; ORGANISM: Centruroides sculpturatus
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (5)..(262)
; OTHER INFORMATION: Product= Sodium-channel modifier toxin precursor
; OTHER INFORMATION: In the mature peptide, the last Cys is amidated, and the last Gly
; OTHER INFORMATION: and the last 2 basic aminoacids are cut
; FEATURE:
; NAME/KEY: 5'clip
; LOCATION: (266)..(320)
; OTHER INFORMATION:
; FEATURE:
; NAME/KEY: 5'UTR
; LOCATION: (1)..(4)
; OTHER INFORMATION:
; FEATURE:
; NAME/KEY: mat_peptide

```
; LOCATION: (62)..()
; OTHER INFORMATION: Product= Sodium-channel modifier toxin
; FEATURE:
; NAME/KEY: sig_peptide
; LOCATION: (5)..(61)
; OTHER INFORMATION:
; PUBLICATION INFORMATION:
; AUTHORS: Corona, M., Valdez-Cruz, N.A., Merino, E., Zurita, M. & Possani L.D.
; TITLE: Genes and peptides from the scorpion Centruroides sculpturatus Ewing,
; TITLE: that recognize Na+-channels
; JOURNAL: Toxicon
; VOLUME: 39
; ISSUE: 12
; PAGES: 1893-1898
; DATE: 2001-12-01
; DATABASE ENTRY DATE:
; RELEVANT RESIDUES: (5)..(262)
US-10-721-793-193
```

```
Query Match           80.8%;   Score 155.2; DB 9; Length 320;
Best Local Similarity 88.0%;   Pred. No. 2.6e-41;
Matches 169; Conservative   0; Mismatches  23; Indels   0; Gaps   0;

Qy      1 AAAGACGGTTATCTGGTGGACAAGACGGGCTGCAAATACACTTGCTCGGATATTGGGAGAA 60
          ||||||||||||||||||||||| |||||| |||||||||||||||||||||||||||||
Db     62 AAGGAAGGTTATCTGGTGGACGTAAAGGGCTGCAAAAAAAATTGCTGGAAAATTGGGAGAT 121

Qy     61 AACAAATACTGCAATAGGAATGCACATGGAAGCACCGAGGAGGTAATTACGGCTATTGC 120
          |||||| |||||||||||||||||| |||||||||||||||||||||| |||||||||||
Db    122 AACGATTATTGCAATAGGGATGTAAATGAAGCACATGGAGGTAGTTACGGCTTACGGCTATTGC 181

Qy    121 TACGGATTTGGGTGCTATTGCGAAGGATTGTCCGATAGTACACCGACTTGGCCCCCTTTCT 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    182 TACGGATTTGGGTGCTATTGCGAAGGATTGCCCGATAGTACACAGACTTGGCCCCCTTCCT 241

Qy    181 AATAAAAGATGC 192
          |||||| ||||
Db    242 AATAAAACATGC 253
```

```
RESULT 9
US-10-721-793-47
; Sequence 47, Application US/10721793
; Publication No. US2005006533A1
; GENERAL INFORMATION:
; APPLICANT: Corona Villegas, Miguel
; APPLICANT: Garcia Rodriguez, Ma Consuelo
; APPLICANT: Valdez Cruz, Norma Adriana
; APPLICANT: Gurrola Briones, Georgina
; APPLICANT: Becerril Lujan, Baltazar
; APPLICANT: Possani Postay, Lourival Domingos
; TITLE OF INVENTION: Recombinant Immunogens for the Generation of Antivenoms to the
; TITLE OF INVENTION: Venom of Scorpions of the Genus Centruroides
; FILE REFERENCE: 2099.0070001
; CURRENT APPLICATION NUMBER: US/10/721,793
; CURRENT FILING DATE:  2003-11-26
; PRIOR APPLICATION NUMBER: US 60/430,067
; PRIOR FILING DATE: 2002-12-02
; SOFTWARE: PatentIn version 3.1
; NUMBER OF SEQ ID NOS: 294
SEQ ID NO 47
; LENGTH: 192
; TYPE: DNA
; ORGANISM: Centruroides exilicauda
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (1)..(192)
; OTHER INFORMATION: Product= Sodium-channel modifier toxin
US-10-721-793-47
```

```
Query Match           79.2%;   Score 152; DB 9; Length 192;
Best Local Similarity 87.0%;   Pred. No. 2.5e-40;
Matches 167; Conservative   0; Mismatches  25; Indels   0; Gaps   0;
```

```
  1 AAAGACGGTTATCTGGTGGACAAGACGGGCTGCAAATACACTTGCTCGGATATTGGGAGAA 60
    |||||||||||||||||||||||  |||||| |||||||||||||||||||||||||||||
  1 AAGGACGGTTATCTGGTGGAGTGCACATAGGAAGCACCGAGGAGGTAATTACGGCTATTGC 60

 61 AACAAATACTGCAATAGGGAATGCAAATGAAGCACATGGAGGTAGTTACGGCTTACGGCTATTGC 120
    |||||| ||||||||||||||||||||  |||||||||||||||||||| |||||||||||
 61 AACAAATTCTGCAATAGGGAATGCAAATGAAGCACATGGAGGTAGTTACGGCTTACGGCTATTGC 120

121 TACGGATTTGGGTGCTATTGCGAAGGATTGTCCGATAGTACACCGACTTGGCCCCCTTTCT 180
    ||| |||||||||||||||||||||||||||||| ||||||||||||||||||||||||||
121 TATTTTTTTGGGTGCTATTGCGAAGGATTGCCCGATAGTACACCGACTTGGCCCCCTTCCT 180

181 AATAAAAGATGC 192
    |||||| ||||
181 AATAAATCATGC 192
```

```
RESULT 10
US-10-721-793-45
; Sequence 45, Application US/10721793
; Publication No. US2005006533A1
; GENERAL INFORMATION:
; APPLICANT: Corona Villegas, Miguel
; APPLICANT: Garcia Rodriguez, Ma Consuelo
; APPLICANT: Valdez Cruz, Norma Adriana
; APPLICANT: Gurrola Briones, Georgina
; APPLICANT: Becerril Lujan, Baltazar
; APPLICANT: Possani Postay, Lourival Domingos
; TITLE OF INVENTION: Recombinant Immunogens for the Generation of Antivenoms to the
; TITLE OF INVENTION: Venom of Scorpions of the Genus Centruroides
; FILE REFERENCE: 2099.0070001
; CURRENT APPLICATION NUMBER: US/10/721,793
; CURRENT FILING DATE:  2003-11-26
; PRIOR APPLICATION NUMBER: US 60/430,067
; PRIOR FILING DATE: 2002-12-02
; SOFTWARE: PatentIn version 3.1
; NUMBER OF SEQ ID NOS: 294
SEQ ID NO 45
; LENGTH: 258
; TYPE: DNA
; ORGANISM: Centruroides exilicauda
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (1)..(204)
; OTHER INFORMATION: Product= Sodium-channel modifier toxin precursor
; OTHER INFORMATION: In the mature peptide, the last Cys is amidated, and the last Gl
; OTHER INFORMATION: and the last 2 basic aminoacids are cut
; FEATURE:
; NAME/KEY: 3'UTR
; LOCATION: (205)..(258)
; OTHER INFORMATION:
US-10-721-793-45
```

```
Query Match           79.2%;   Score 152; DB 9; Length 258;
Best Local Similarity 87.0%;   Pred. No. 2.8e-40;
Matches 167; Conservative   0; Mismatches  25; Indels   0; Gaps   0;

Qy      1 AAAGACGGTTATCTGGTGGACAAGACGGGCTGCAAATACACTTGCTCGGATATTGGGAGAA 60
          |||||||||||||||||||||||  |||||| |||||||||||||||||||||||||||||
Db      1 AAGGACGGTTATCTGGTGGAGTGCACATAGGAAGCACCGAGGAGGTAATTACGGCTATTGC 60

Qy     61 AACAAATACTGCAATAGGGAATGCAAATGAAGCACATGGAGGTAGTTACGGCTTACGGCTATTGC 120
          |||||| ||||||||||||||||||||  |||||||||||||||||||| |||||||||||
Db     61 AACAAATTCTGCAATAGGGAATGCAAATGAAGCACATGGAGGTAGTTACGGCTTACGGCTATTGC 120

Qy    121 TACGGATTTGGGTGCTATTGCGAAGGATTGTCCGATAGTACACCGACTTGGCCCCCTTTCT 180
          ||| |||||||||||||||||||||||||||||| ||||||||||||||||||||||||||
Db    121 TATTTTTTTGGGTGCTATTGCGAAGGATTGCCCGATAGTACACCGACTTGGCCCCCTTCCT 180

Qy    181 AATAAAAGATGC 192
          |||||| ||||
Db    181 AATAAATCATGC 192
```

RESULT 11
US-10-721-793-43
; Sequence 43, Application US/10721793
; Publication No. US20050065331A1
; GENERAL INFORMATION:
; APPLICANT: Corona Villegas, Miguel
; APPLICANT: Garcia Rodriguez, Ma Consuelo
; APPLICANT: Valdez Cruz, Norma Adriana
; APPLICANT: Gurrola Briones, Georgina
; APPLICANT: Becerril Lujan, Baltazar
; APPLICANT: Possani Postay, Lourival Domingos
; TITLE OF INVENTION: Recombinant Immunogens for the Generation of Antivenoms to the
; TITLE OF INVENTION: Venom of Scorpions of the Genus Centruroides
; FILE REFERENCE: 2099.0070001
; CURRENT APPLICATION NUMBER: US/10/721,793
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 60/430,067
; PRIOR FILING DATE: 2002-12-02
; NUMBER OF SEQ ID NOS: 294
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 43
; LENGTH: 192
; TYPE: DNA
; ORGANISM: Centruroides exilicauda
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (1)..(192)
; OTHER INFORMATION: Product= Sodium-channel modifier toxin
US-10-721-793-43

Query Match   78.3%; Score 150.4; DB 9; Length 192;
Best Local Similarity   86.5%; Pred. No. 8.4e-40;
Matches 166; Conservative   0; Mismatches 26; Indels   0; Gaps   0;

```
Qy      1 AAAGACGGTTATCTGGTGGACAAGACGGGCTGCAAATACACTTGCTCGGATATTGGGAGAA 60
          || ||||||||| |||||||  |||||||||||||| |||| |||||| || ||||||||||
Db      1 AAGGACGGTTATCCGGTGGAGTCACGGGCTGCAAAAAGTCTTGCTATAAAGTCGGGAGAA 60

Qy     61 AACAAATACTGCAATAGGGAATGCACATGGAAGCACATGCACCGAGGAGTAATTACGGCTATTGC 120
          ||||||| |||||||||||||||||  |  ||||||   |  |||||||||  |||||||||||||
Db     61 AACAAATTCTGCAATAGGGAATGCAAAATGAAGCAAAATGAAGCACCGAGGAGTAGTTACGGCTATTGC 120

Qy    121 TACGGATTTGGGTGCTATTGCGAAGGATTGTCCGATAGTACACCGACTTGCCCCTTTCT 180
          || |||||||||||||||||||||||||||  |||| ||||||||||||||||||| ||||
Db    121 TATTTTTTTGGGTGCTATTGCGAAGGATTGGCCGAAAGTACACCGACTTGCCCCCTTCCT 180

Qy    181 AATAAAGATGC 192
          ||||| ||||
Db    181 AATAAATCATGC 192
```

RESULT 12
US-10-721-793-41
; Sequence 41, Application US/10721793
; Publication No. US20050065331A1
; GENERAL INFORMATION:
; APPLICANT: Corona Villegas, Miguel
; APPLICANT: Garcia Rodriguez, Ma Consuelo
; APPLICANT: Valdez Cruz, Norma Adriana
; APPLICANT: Gurrola Briones, Georgina
; APPLICANT: Becerril Lujan, Baltazar
; APPLICANT: Possani Postay, Lourival Domingos
; TITLE OF INVENTION: Recombinant Immunogens for the Generation of Antivenoms to the
; TITLE OF INVENTION: Venom of Scorpions of the Genus Centruroides
; FILE REFERENCE: 2099.0070001
; CURRENT APPLICATION NUMBER: US/10/721,793
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 60/430,067
; PRIOR FILING DATE: 2002-12-02
; NUMBER OF SEQ ID NOS: 294
; SOFTWARE: Patentin version 3.1

; SEQ ID NO 41
; LENGTH: 254
; TYPE: DNA
; ORGANISM: Centruroides exilicauda
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (1)..(204)
; OTHER INFORMATION: Product= Sodium-channel modifier toxin precursor
; OTHER INFORMATION: In the mature peptide, the last Cys is amidated, and the last Gly
; OTHER INFORMATION: and the last 2 basic aminoacids are cut
; FEATURE:
; NAME/KEY: 3'UTR
; LOCATION: (205)..(254)
; OTHER INFORMATION:
US-10-721-793-41

Query Match   78.3%; Score 150.4; DB 9; Length 254;
Best Local Similarity   86.5%; Pred. No. 9.5e-40;
Matches 166; Conservative   0; Mismatches 26; Indels   0; Gaps   0;

```
Qy      1 AAAGACGGTTATCTGGTGGACAAGACGGGCTGCAAATACACTTGCTCGGATATTGGGAGAA 60
          || ||||||||| |||||||  |||||||||||||| |||| |||||| || ||||||||||
Db      1 AAGGACGGTTATCCGGTGGAGTCACGGGCTGCAAAAAGTCTTGCTATAAATTCGGGAGAA 60

Qy     61 AACAAATACTGCAATAGGGAATGCACATGGAAGCACATGCACCGAGGAGTAATTACGGCTATTGC 120
          ||||||| |||||||||||||||||  |  ||||||   |  |||||||||  |||||||||||||
Db     61 AACAAATTCTGCAATAGGGAATGCAAAATGAAGCAAAATGAAGCACCGAGGAGTAGTTACGGCTATTGC 120

Qy    121 TACGGATTTGGGTGCTATTGCGAAGGATTGTCCGATAGTACACCGACTTGCCCCTTTCT 180
          || |||||||||||||||||||||||||||  |||| ||||||||||||||||||| ||||
Db    121 TATTTTTTTGGGTGCTATTGCGAAGGATTGGCCGAAAGTACACCGACTTGCCCCCTTCCT 180

Qy    181 AATAAAGATGC 192
          ||||| ||||
Db    181 AATAAATCATGC 192
```

RESULT 13
US-10-721-793-91
; Sequence 91, Application US/10721793
; Publication No. US20050065331A1
; GENERAL INFORMATION:
; APPLICANT: Corona Villegas, Miguel
; APPLICANT: Garcia Rodriguez, Ma Consuelo
; APPLICANT: Valdez Cruz, Norma Adriana
; APPLICANT: Gurrola Briones, Georgina
; APPLICANT: Becerril Lujan, Baltazar
; APPLICANT: Possani Postay, Lourival Domingos
; TITLE OF INVENTION: Recombinant Immunogens for the Generation of Antivenoms to the
; TITLE OF INVENTION: Venom of Scorpions of the Genus Centruroides
; FILE REFERENCE: 2099.0070001
; CURRENT APPLICATION NUMBER: US/10/721,793
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 60/430,067
; PRIOR FILING DATE: 2002-12-02
; NUMBER OF SEQ ID NOS: 294
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 91
; LENGTH: 198
; TYPE: DNA
; ORGANISM: Centruroides noxius
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (1)..(198)
; OTHER INFORMATION: Product= Sodium-channel modifier toxin
US-10-721-793-91

Query Match   75.7%; Score 145.4; DB 9; Length 198;
Best Local Similarity   87.7%; Pred. No. 4e-38;
Matches 171; Conservative   0; Mismatches 21; Indels   3; Gaps   1;

```
Qy      1 AAAGACGGTTATCTGGTGGACAA---GACGGCTGCAAATACACTTGCTCGGATATTGGGA 57
          || |||||||||||||||||||||   |||| || |||| |||| |||||||||||| ||||
```

Db   122 GAAACAAAAACTGCGATATGGAATGGAATGCAAAGCGAAGAACCAAGAGAGGAGTAGTTACGGCTAT 181

Qy   118 TGCTACGGATTTGGGTGCTATTGCGAAGGATTGTCCGATAGTACACCGACTTGGCCCCTT 177
          |||||||||||||||||||||| ||| ||||| || |||||||||||||||||||||||
Db   182 TGCTACGGATTTGGGTGCTATTGTGAAGGATTGTCCGATAGTACACCGACTTGGCCCCTT 241

Qy   178 TCTAATAAAAGATGC 192
          ||||||||||||||
Db   242 CCTAATAAAACATGC 256

RESULT 15
US-10-721-793-111
; Sequence 111, Application US/10721793
; Publication No. US20050065331A1
; GENERAL INFORMATION:
;   APPLICANT: Corona Villegas, Miguel
;   APPLICANT: Garcia Rodriguez, Ma Consuelo
;   APPLICANT: Valdez Cruz, Norma Adriana
;   APPLICANT: Gurrola Briones, Georgina
;   APPLICANT: Becerril Lujan, Baltazar
;   APPLICANT: Possani Postay, Lourival Domingos
;   TITLE OF INVENTION: Recombinant Immunogens for the Generation of Antivenoms for the Genus Centruroides
;   TITLE OF INVENTION: Venom of Scorpions of the Genus Centruroides
;   FILE REFERENCE: 2099.0070001
;   CURRENT APPLICATION NUMBER: US/10/721,793
;   CURRENT FILING DATE: 2003-11-26
;   PRIOR APPLICATION NUMBER: US 60/430,067
;   PRIOR FILING DATE: 2002-12-02
;   SOFTWARE: PatentIn version 3.1
;   NUMBER OF SEQ ID NOS: 294
; SEQ ID NO 111
;   LENGTH: 189
;   TYPE: DNA
;   ORGANISM: Centruroides elegans
;   FEATURE:
;   NAME/KEY: CDS
;   LOCATION: (1)..(189)
;   OTHER INFORMATION: Product= Sodium-channel modifier toxin
US-10-721-793-111

  Query Match   66.0%; Score 126.8; DB 9; Length 189;
  Best Local Similarity   82.8%; Pred. No. 6.4e-32;
  Matches 159; Conservative 0; Mismatches 27; Indels 6; Gaps 1;

Qy   1 AAAGACGGTTATCTGGTGGACAAGACGGGCTGCAAATCACTTGCTGGATATTGGGAGAA 60
          ||||||||||||||| |||||| ||||||||||| ||||||||||||| ||||||||||
Db   4 AAGGACGGTTATCTGGTGAACAAGACGGCGGCTGCAAATACAATTGCTGGATATTGGGAGAA 63

Qy   61 AACAAATACTGCAATAGGGAATGCACATGGAAGCACCGAGAGAGTAATTACGGCTATTGC 120
          |||||||||||||||||| ||| ||| |||||||||||||||||||| ||||| ||||||
Db   64 AACAAATACTGCAATTCGGAATGC------AAAGAGGTAGGTGCTGGTTACGGCTATTGC 117

Qy   121 TACGGATTTGGGTGCTATTGCGAAGGATTGTCCGAAGATAGTACACCGACTTGGCCCCTTTCT 180
          ||||||||||||||| ||||||| ||||||| ||||| || |||||||||||||||||||
Db   118 TATGCTTTTGGGTGCTATTGCGAAGGATTACCCGAAAGCCGACTGACCTGGCCCCTTTCT 177

Qy   181 AATAAAAGATGC 192
          |||||| ||||
Db   178 GATAAACATGC 189

Search completed: January 22, 2006, 01:12:50
Job time : 2178 secs

Db   122 GAAACAAAAACTGCGATATGGAATGGAATGCAAAGCGAAGAACCAAGAGAGGAGTAGTTACGGCTAT 181

Qy   1 AAGGAAGGTTATCTGGTGAACAAAGCACAGGCTGTAAATACAACTGCTTGATATTGGGA 60
          ||||||||||||||||||||| |||||||||| ||| ||||||||||||||||||
Db   58 GAAACAAATACTGCAATAGGGAATGCACATGCCACCGAGAGCCGCCGAGGTAATTACGGCTAT 117

Qy   61 TGCTACGGATTTGGGTGCTATTGCGAAGGATTGTCCGATAGTACACCGACTTGGCCCCTT 117
          ||||||||||||||||||| || ||| |||||||||||||||||||||||||||||||
Db   61 GAAACAAAAACTGCGATATGGAATGCAAAGCGAAGAACCAAGAGAGGAGTAGTTACGGCTAT 120

Qy   118 TGCTACGGATTTGGGTGCTATTGCGAAGGATTGTCCGATAGTACACCGACTTGGCCCCTT 177
          |||||||||||||||||||| ||| ||| |||||||||||||||||||||||||||||
Db   121 TGCTACGGATTTGGGTGCTATTGTGTGAAGGATTGTCCGATAGTACACCGACTTGGCCCCTT 180

Qy   178 TCTAATAAAAGATGC 192
 |||||||||||||
Db   181 CCTAATAAAACATGC 195

RESULT 14
US-10-721-793-89
; Sequence 89, Application US/10721793
; Publication No. US20050065331A1
; GENERAL INFORMATION:
;   APPLICANT: Corona Villegas, Miguel
;   APPLICANT: Garcia Rodriguez, Ma Consuelo
;   APPLICANT: Valdez Cruz, Norma Adriana
;   APPLICANT: Gurrola Briones, Georgina
;   APPLICANT: Becerril Lujan, Baltazar
;   APPLICANT: Possani Postay, Lourival Domingos
;   TITLE OF INVENTION: Recombinant Immunogens for the Generation of Antivenoms for the Genus Centruroides
;   TITLE OF INVENTION: Venom of Scorpions of the Genus Centruroides
;   FILE REFERENCE: 2099.0070001
;   CURRENT APPLICATION NUMBER: US/10/721,793
;   CURRENT FILING DATE: 2003-11-26
;   PRIOR APPLICATION NUMBER: US 60/430,067
;   PRIOR FILING DATE: 2002-12-02
;   SOFTWARE: PatentIn version 3.1
;   NUMBER OF SEQ ID NOS: 294
; SEQ ID NO 89
;   LENGTH: 323
;   TYPE: DNA
;   ORGANISM: Centruroides noxius
;   FEATURE:
;   NAME/KEY: CDS
;   LOCATION: (5)..(265)
;   OTHER INFORMATION: Product= Sodium-channel modifier toxin precursor
;   OTHER INFORMATION: In the mature peptide, the last Ser is amidated, and the last Gly
;   OTHER INFORMATION: and the last basic aminoacid are cut
;   FEATURE:
;   NAME/KEY: 3'UTR
;   LOCATION: (269)..(323)
;   OTHER INFORMATION:
;   FEATURE:
;   NAME/KEY: 5'UTR
;   LOCATION: (1)..(4)
;   OTHER INFORMATION:
;   FEATURE:
;   NAME/KEY: mat_peptide
;   LOCATION: (62)..()
;   OTHER INFORMATION: Product= Sodium-channel modifier toxin
;   FEATURE:
;   NAME/KEY: sig_peptide
;   LOCATION: (5)..(61)
;   OTHER INFORMATION:
US-10-721-793-89

  Query Match   75.7%; Score 145.4; DB 9; Length 323;
  Best Local Similarity   87.7%; Pred. No. 4.9e-38;
  Matches 171; Conservative 0; Mismatches 21; Indels 3; Gaps 1;

Qy   1 AAAGACGGTTATCTGGTGGACAA---GACGGGCTGCAAATCACTTGCTGGATATTGGGA 57
          |||||||||||||||||| |||||| ||||||||||||||||||||||||
Db   2 AAGGAAGGTTATCTGGTGAACAAAGCACAGGCTGTAAATACAACTGCTTGATATTGGGA 121

Qy   58 GAAACAAATACTGCAATAGGGAATGCACATGCCACCGAGAGCCGCCGAGGTAATTACGGCTAT 117
          ||||||||||||||||||| ||| ||| |||||||||||||||||||||||||||||
Db   58 GAAACAAATACTGCAATAGGGAATGCACAT... 117

Alignments:

C1 C2   C3 C4   C5 C6 C7   C8

Long-chain toxins specific for sodium channels:

A	B	C	D
004	Cex1	KEGYLVSKSTGCKYECFWLGKNEGCDKECKAPNQGGGYGYCHAFACWCENLPESTPTYPIPGKSC---	53.8
008	Cex2	KEGYLVSKSTGCKYECFWLGKNEGCDKECKAPNQGGGYGYCHAFACWCENLPESTPTYPIPGKSC---	53.8
036	Cex7	REGYLVSKSTGCKYECFWLGKNEGCDKECKAPNQGGGYGYCHAFACWCENLPESTPTYPIPGKSC---	52.3
028	Cex5	KDGYLVSKSTGCKYECFWLGKNEGCDKECKAPNQGGGYGYCHAFACWCENLPESTPTYPIPGKSC---	55.3
104	Ce6	KEGYLVNKSTGCKYSCVLLGKNENCDKECKAKNQGGSYGYCYAFGCWCEGLPESTPTYPIPGKSC---	60.0
108	Ce6b	KDGYLVNKSTGCKYSCGKLGENEHCDKECKAKNQGGSYGYCYAFGCWCEGLPESTPTYPIPGKSC---	63.0
148	CsEv3b	KEGYLVNKSTGCKYGCLKLGENEGCDKECKAKNQGGSYGYCYAFACWCEGLPESTPTYPLPNKSC---	63.0
176	CsEv2a	KEGYLVNKSTGCKYGCLKLGENEGCDKECKAKNQGGSYGYCYAFACWCEGLPESTPTYPLPNKSCS--	62.1
164	CsEv2d	KEGYLVNKSTACKYGCLKLGENEGCDKECKAKNQGGSYGYCYAFACWCEGLPESTPTYPLPNKSCS--	60.6
160	CsEv2b	REGYLVNKSTGCKYGCLKLGENEGCDKECKAKNQGGSYGYCYAFACWCEGLPESTPTYPLPNKSCS--	60.6
156	CsEv2c	KEGYLVNKSTGCKYGCLKLGENEGCDKECKAENQGGSYGYCYAFACWCEGLPESTPTYPLPNKSCS--	60.6
100	Ce5	KEGYLVNKSTGCKYGCLLLRKNEGCDKECKAKNQGGSYGYCYSFACWCEGLPESTPTYPLPNKSCSKK	57.3
024	Cex4	KEGYLVNKSTGCKYECFWLGKNEFCDKECKAKNQGGSYGYCYSFACWCEGLPESTSTYPLPNKSC---	60.0
032	Cex6	REGYLVNKSTGCKYECFWLGKNEFCDKECKAKNQGGSYGYCYSFACWCEGLPESTSTYPLPNKSC---	58.4
020	Cex3	KDGYLVNKSTGCKYECFWLGKNEFCDKECKAKNQGGSYGYCYSFACWCEGLPESTSTYPLPNKSC---	61.5
068	C115b	KEGYLVNKSTGCKYGCFWLGKNENCDKECKAKNQGGSYGYCYSFACWCEGLPDSTPTYPLPNKSCS--	62.1
072	C115c	KEGYLVNKSTGCKYGCFWLGKNENCDMECKAKNQGGSYGYCYSFACWCEGLPDSTPTYPLPNKSCS--	62.1
140	CsEv1d	KDGYLVNKSTGCKYDCFWLGKNEHCDLECKAKNQGGSYGYCYAFACWCEGLPESTPTYPLPNKSC---	63.0
144	CsEv1c	KDGYLVKKSTGCKYDCFWLGKNEHCDLECKAKNQGGSYGYCYAFACWCEGLPESTPTYPLPNKSC---	63.0
168	CsEv1b	KEGYLVKKSDGCKYDCFWLGKNEHCDTECKAKNQGGSYGYCYAFACWCEGLPESTPTYPLPNKSC---	60.0
172	CsEv1e	KEGYLVKKSDGCKYDCFWLGENEGCDKECKAKNQGGSYGYCYAFACWCEGLPESTPYTPLPNKSC---	60.0
084	C118	KEGYLVKKSNGCKYECFKLGENEHCDTECKAPNQGGSYGYCDTFECWCEGLPESTPTWPLPNKSC---	60.0
092	Cn10b	KEGYLVNKSTGCKYNCLILGENKNCDMECKAKNQGGSYGYCYGLGCYCEGLSDSTPTWPLPNKTCS--	74.2
124	Cg1	KDGYLVKKSDGCKYGCMLKIGDAGCDKECKAPNQGGSYGYCYLLGCWCEGMPESTPTYPLPGKSC---	52.3
128	Cg1b	KDGYLVKESDGCKYGCMLKIGDAGCDKECKAPNQGGSYGYCYLLGCWCEGMPESTPTYPLPGKSC---	52.3
136	Cg3	KDGYLVKKSDGCKYGCVMLVGDSGCDTECKAKNQGGKKCWCYAFGCWCTGMPDSTQVYPLPDKSC---	49.2
016	Cex13	KDGYLVIIKTGCKYNCYILGKNKYCNSEC--KEVGAGYGYCYAFGCWCEGLPESIPTWPLPDKTCGTK	66.1
112	Ce7	KDGYLVN-KTGCKYNCWILGENKYCNSWC--KEVGAGYGYCYAFGCYCEGLPESVLTWPLSDKTC---	73.4
040	Cex8	KEGYLVNIYTGCKYSCWLLGENEYCIAEC--KEIGAGYGYCHGFGCWCEQFPENKPSYPYPEKSC---	55.3
052	Cex11	KEGYPVNIYTGCKYSCWLLGENEYCIAEC--KEIGAGYGYCHGFGCWCEQFPENKPSYPYPEKSC---	53.8
080	C117	KEGYLVNTYTGCKYICWKLGENKYCIDEC--KEIGAGYGYCYGFGCYCEGFPENKPTWPLPNKTC---	67.6
044	Cex9	KDGYPVE-VTGCKKSCYKLGENKFCNRECKMKHRGGSYGYCYFFGCYCEGLAESTPTWPLPNKSC---	75.0
048	Cex10	KDGYLVE-VTGCKKSCYKLGENKFCNRECKMKHRGGSYGYCYFFGCYCEGLAESTPTWPLPNKSC---	76.5
152	CsE1a	KDGYLVE-KTGCKKTCYKLGENDFCNRECKWKHIGGSYGYCYGFGCYCEGLPDSTQTWPLPNKTC---	79.6
196	CsE1x	KEGYLVD-VKGCKKNCWKLGDNDYCNRECKWKHIGGSYGYCYGFGCYCEGLPDSTQTWPLPNKTC---	76.5
116	Ce13	KDGYLVD-KTGCKYTCWILGENKYCNRECTWKHRGGNYGYCYGFGCYCEGLSDSTPTWPLSNKRC---	100.0
120	Ce13b	KDGYLVD-KTGCKYTCWILGENKYCNRECTWKHRGGNYGYCYCGGCYCEGLSDSTPTWPLPNKRC---	95.3
056	C112b	KEGYLVNHSTGCKYECYKLGDNDYCLRECKQQYGKGAGGYCYAFGCWCTHLYEQAVVWPLPKKTCN--	51.5
088	Cn4b	KEGYIVNSYTGCKYECLKLGDNDYCLRECKQQYGKGAGGYCYAFGCWCTHLYEQAVVWPLKNKTCN--	51.5
064	C114	KEGYIVNYHDGCKYECYKLGDNDYCLRECKLRYGKGAGGYCYAFGCWCTHLYEQAVVWPLPKKRCN--	50.0
096	Ce3	KEGYIVNYHDGCKYECYKLGDNDYCLRECKLRYGKGAGGYCYAFGCWCTHLYEQAVVWPLPKKRCN--	50.0
192	CsE3	KEGYIVNYHTGCKYECFKLGDNDYCLRECKLRHGKGSGGYCYAFGCWCTHLYEQAVVWPLPKKKCN--	51.5
060	C113	KEGYIVNYYDGCKYACLKLGDNDYCLRECKARYYKSAGGYCYAFACWCTHLYEQAVVWPLPNKTCY--	48.4
076	C116	KEGYLVNMKTGCKYGCYELGDNGYCDRKC--KAESGNYGYCYTVGCWCEGLPNSKPTWPLPGKSCS--	62.1
188	CsE8	EKGYLVHEDTGCRYKCTFSGENSYCDKECK--SQGGDSGICQSKACYCQGLPEDTKTWPLIGKLC---	49.2
132	Cg2	KDGYLVNKSTGCKYSCIENINDSHCNEECISSIRKGSYGYCYKFYCYCIGMPDSTQVYPIPGKTCSTE	50.0
180	CsE9b	EDGYLFDKRKRCTLECIDKTGDKNCDRNCK--NEGGSFGKCSYFACWCKGLPGITPISRTPGKTCKI-	35.8
184	CsE9	EDGYLFDKRKRCTLECIDMTGDKNCDRNCK--KEGGSFGKCSYFACWCKGLPGITPISRTPGKTCKI-	35.8
012	Cex12	NDGYLFDKRKRCTLECIDKTGDKNCDRNCK--KEGGSFGKCSYSACWCKGLPGITPISRTPGKTC---	35.3

Column A= SEQ. ID. No.
Column B= Clone name
Column C= amino acid sequences encoded by the DNAs
Column D= Is the percent of identity to SEQ.ID.NO:116, the amino acid sequence (mature peptide) encoded by the elected sequence SEQ.ID.NO:115.